Results 121 to 130 of about 5,479 (195)

The Real‐World Safety Profile of Haloperidol: A Comprehensive Pharmacovigilance Analysis Using the Large‐Scale FAERS Database

open access: yesCNS Neuroscience &Therapeutics, Volume 32, Issue 10, October 2026.
This first comprehensive FAERS‐based pharmacovigilance analysis of haloperidol over two decades characterized the real‐world safety profile across 9916 reports. Strong signals were found for nervous, psychiatric, and cardiac disorders. Known risks were confirmed and novel signals revealed. Sex‐ and age‐specific vulnerabilities were identified. Findings
Nengping Luo   +3 more
wiley   +1 more source

The genetic architecture of epilepsy across molecular mechanisms and clinical heterogeneity

open access: yesEpilepsia Open, Volume 11, Issue 5, Page 1395-1412, October 2026.
Abstract Epilepsy comprises a highly heterogeneous group of neurological disorders unified by a persistent predisposition to recurrent seizures, yet driven by remarkably diverse genetic, molecular, and network‐level mechanisms. Advances in genomic technologies have revealed that epilepsy arises from a multilayered genetic architecture encompassing rare
Mohammad Reza Seyedtaghia   +4 more
wiley   +1 more source

hERG Central

open access: yes
human Ether-à-go-go related gene (hERG) inhibition data obtained from a primary screen against more than 300,000 ...
Birnbaum, Ben
core   +1 more source

Do Stimulants Promote Arrhythmic Risk: Insights From a Human‐Induced Pluripotent Stem Cell‐Derived Cardiomyocyte Model

open access: yesJournal of Arrhythmia, Volume 42, Issue 5, October 2026.
At clinically relevant plasma concentrations, stimulant medications produced minimal effects on conduction velocity but modulated automaticity and repolarization in a hiPSC‐derived cardiomyocyte (hiPSC‐CM) model. These findings provide a foundation for future investigations of stimulant‐associated cardiac safety and support the utility of hiPSC‐CM ...
Alia Arslanova   +5 more
wiley   +1 more source

Coexpression of B-RAF increased hERG-HA protein abundance at the surface of hERG-expressing Xenopus oocytes.

open access: yes, 2014
A. Confocal images of hERG-HA protein cell surface expression in Xenopus oocytes injected with water (left panel), with cRNA encoding hERG-HA alone (middle panel) or with cRNA encoding hERG-HA together with wild-type B-RAF (right panel).
Tatsiana Pakladok (311653)   +6 more
core   +1 more source

Multi-laboratory comparisons of manual patch clamp hERG data generated using standardized protocols and following ICH S7B Q&A 2.1 best practices

open access: yesScientific Reports
Acute block of hERG channels is the most common mechanism underlying drug-induced QTC prolongation and potentially fatal Torsade de Pointes arrhythmia. Updates to ICH E14 Q&As now allow for using negative nonclinical data, including hERG, to support QTC ...
Claudia Alvarez Baron   +25 more
doaj   +1 more source

Tripterine Liposome Exerts Antitumor and Immunomodulatory Effects in Pancreatic Ductal Adenocarcinoma

open access: yesMedComm, Volume 7, Issue 10, October 2026.
Tripterine liposome (TP‐lipo) exerts anti‐pancreatic ductal adenocarcinoma (PDAC) effects through direct suppression of tumor cells and modulation of the tumor microenvironment (TME). TP‐lipo induces apoptosis and inhibits the clonogenicity, migration, and invasion of KPC cells in vitro.
Lirui Tang   +8 more
wiley   +1 more source

Preclinical and Toxicology Studies of LPM7100328, a Novel Oral GnRH Antagonist

open access: yesPharmacology Research &Perspectives, Volume 14, Issue 5, October 2026.
ABSTRACT LPM7100328 is a novel oral GnRH antagonist being developed for the prevention of premature luteinizing hormone (LH) surges in women undergoing controlled ovarian stimulation. The studies presented herein reported assessment of safety in favor of human clinical trials.
Yao Wang   +9 more
wiley   +1 more source

Implementation of the In Vitro Seizure Liability Assay (iLAseizure) in Drug Discovery and Development: Mechanism of Action Case Studies

open access: yesPharmacology Research &Perspectives, Volume 14, Issue 5, October 2026.
ABSTRACT Central nervous system (CNS) liabilities remain a significant cause of attrition during small molecule drug development. We previously developed the in vitro seizure liability assay (iLAseizure), a new approach methodology (NAM) comprising a human induced pluripotent stem cell neuron microelectrode array (MEA) assay coupled with a panel of ...
Kimberly Rockley   +5 more
wiley   +1 more source

Application of an Open‐Source Modular Framework for Pharmacokinetic, Pharmacodynamic, and Safety Simulations to Anti‐Tuberculosis Drugs

open access: yesCPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 10, October 2026.
ABSTRACT Tuberculosis (TB) treatment requires long‐term multidrug regimens where dosing, efficacy, and safety optimization remain challenging. This tutorial establishes an integrated, open‐source, modular framework connecting high‐throughput PBPK (HT‐PBPK) simulations, mechanistic PBPK models, pharmacodynamic endpoints, and safety predictions for anti ...
Marco Siccardi   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy